762 related articles for article (PubMed ID: 26652893)
1. Real-world dosing and drug costs with everolimus or axitinib as second targeted therapies for advanced renal cell carcinoma: a retrospective chart review in the US.
Pal SK; Jonasch E; Signorovitch JE; Reichmann WM; Li N; Liu Z; Perez JR; Vogelzang NJ
J Med Econ; 2016; 19(5):462-8. PubMed ID: 26652893
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of everolimus and axitinib as second targeted therapies for metastatic renal cell carcinoma in the US: a retrospective chart review.
Vogelzang NJ; Pal SK; Signorovitch JE; Reichmann WM; Li N; Yang C; Liu Z; Perez JR; Jonasch E
Curr Med Res Opin; 2016; 32(4):741-7. PubMed ID: 26744781
[TBL] [Abstract][Full Text] [Related]
3. Lifetime cost of everolimus vs axitinib in patients with advanced renal cell carcinoma who failed prior sunitinib therapy in the US.
Perrin A; Sherman S; Pal S; Chua A; Gorritz M; Liu Z; Wang X; Culver K; Casciano R; Garrison LP
J Med Econ; 2015 Mar; 18(3):200-9. PubMed ID: 25422989
[TBL] [Abstract][Full Text] [Related]
4. Real-World Effectiveness of Everolimus Subsequent to Different First Targeted Therapies for the Treatment of Metastatic Renal Cell Carcinoma: Synthesis of Retrospective Chart Reviews.
Pal SK; Signorovitch JE; Reichmann WM; Li N; Koo V; Liu Z; Perez JR; Vogelzang NJ
Clin Genitourin Cancer; 2016 Apr; 14(2):160-7.e3. PubMed ID: 26707954
[TBL] [Abstract][Full Text] [Related]
5. The Additional Costs per Month of Progression-Free Survival and Overall Survival: An Economic Model Comparing Everolimus with Cabozantinib, Nivolumab, and Axitinib for Second-Line Treatment of Metastatic Renal Cell Carcinoma.
Swallow E; Messali A; Ghate S; McDonald E; Duchesneau E; Perez JR
J Manag Care Spec Pharm; 2018 Apr; 24(4):335-343. PubMed ID: 29578848
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review and Meta-analysis Comparing the Effectiveness and Adverse Effects of Different Systemic Treatments for Non-clear Cell Renal Cell Carcinoma.
Fernández-Pello S; Hofmann F; Tahbaz R; Marconi L; Lam TB; Albiges L; Bensalah K; Canfield SE; Dabestani S; Giles RH; Hora M; Kuczyk MA; Merseburger AS; Powles T; Staehler M; Volpe A; Ljungberg B; Bex A
Eur Urol; 2017 Mar; 71(3):426-436. PubMed ID: 27939075
[TBL] [Abstract][Full Text] [Related]
7. Comparative outcomes of everolimus, temsirolimus and sorafenib as second targeted therapies for metastatic renal cell carcinoma: a US medical record review.
Wong MK; Yang H; Signorovitch JE; Wang X; Liu Z; Liu NS; Qi CZ; George DJ
Curr Med Res Opin; 2014 Apr; 30(4):537-45. PubMed ID: 24329572
[TBL] [Abstract][Full Text] [Related]
8. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial.
Motzer RJ; Escudier B; Tomczak P; Hutson TE; Michaelson MD; Negrier S; Oudard S; Gore ME; Tarazi J; Hariharan S; Chen C; Rosbrook B; Kim S; Rini BI
Lancet Oncol; 2013 May; 14(6):552-62. PubMed ID: 23598172
[TBL] [Abstract][Full Text] [Related]
9. Targeted Therapy for Metastatic Renal Cell Carcinoma.
Afriansyah A; Hamid AR; Mochtar CA; Umbas R
Acta Med Indones; 2016 Oct; 48(4):335-347. PubMed ID: 28143997
[TBL] [Abstract][Full Text] [Related]
10. Targeted therapy for metastatic renal cell carcinoma.
Hofmann F; Hwang EC; Lam TB; Bex A; Yuan Y; Marconi LS; Ljungberg B
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD012796. PubMed ID: 33058158
[TBL] [Abstract][Full Text] [Related]
11. Axitinib versus sorafenib as first-line therapy in patients with metastatic renal-cell carcinoma: a randomised open-label phase 3 trial.
Hutson TE; Lesovoy V; Al-Shukri S; Stus VP; Lipatov ON; Bair AH; Rosbrook B; Chen C; Kim S; Vogelzang NJ
Lancet Oncol; 2013 Dec; 14(13):1287-94. PubMed ID: 24206640
[TBL] [Abstract][Full Text] [Related]
12. Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial.
Escudier B; Michaelson MD; Motzer RJ; Hutson TE; Clark JI; Lim HY; Porfiri E; Zalewski P; Kannourakis G; Staehler M; Tarazi J; Rosbrook B; Cisar L; Hariharan S; Kim S; Rini BI
Br J Cancer; 2014 Jun; 110(12):2821-8. PubMed ID: 24823696
[TBL] [Abstract][Full Text] [Related]
13. Small molecule targeted therapies for the second-line treatment for metastatic renal cell carcinoma: a systematic review and indirect comparison of safety and efficacy.
Dranitsaris G; Schmitz S; Broom RJ
J Cancer Res Clin Oncol; 2013 Nov; 139(11):1917-26. PubMed ID: 24037486
[TBL] [Abstract][Full Text] [Related]
14. Early Tumour Shrinkage: A Tool for the Detection of Early Clinical Activity in Metastatic Renal Cell Carcinoma.
Grünwald V; Lin X; Kalanovic D; Simantov R
Eur Urol; 2016 Dec; 70(6):1006-1015. PubMed ID: 27238653
[TBL] [Abstract][Full Text] [Related]
15. Health economic changes as a result of implementation of targeted therapy for metastatic renal cell carcinoma: national results from DARENCA study 2.
Soerensen AV; Donskov F; Kjellberg J; Ibsen R; Hermann GG; Jensen NV; Fode K; Geertsen PF
Eur Urol; 2015 Sep; 68(3):516-22. PubMed ID: 25533417
[TBL] [Abstract][Full Text] [Related]
16. Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database.
Maroun R; Fleury L; Nachbaur G; Maunoury F; Vanhille JL; Durand-Zaleski I
Curr Med Res Opin; 2017 Oct; 33(10):1755-1762. PubMed ID: 28748721
[TBL] [Abstract][Full Text] [Related]
17. First-line therapy for treatment-naive patients with advanced/metastatic renal cell carcinoma: a systematic review of published randomized controlled trials.
Takyar S; Diaz J; Sehgal M; Sapunar F; Pandha H
Anticancer Drugs; 2016 Jun; 27(5):383-97. PubMed ID: 26886011
[TBL] [Abstract][Full Text] [Related]
18. Cabozantinib versus everolimus, nivolumab, axitinib, sorafenib and best supportive care: A network meta-analysis of progression-free survival and overall survival in second line treatment of advanced renal cell carcinoma.
Amzal B; Fu S; Meng J; Lister J; Karcher H
PLoS One; 2017; 12(9):e0184423. PubMed ID: 28886175
[TBL] [Abstract][Full Text] [Related]
19. Systemic therapy in metastatic renal cell carcinoma.
Bedke J; Gauler T; Grünwald V; Hegele A; Herrmann E; Hinz S; Janssen J; Schmitz S; Schostak M; Tesch H; Zastrow S; Miller K
World J Urol; 2017 Feb; 35(2):179-188. PubMed ID: 27277600
[TBL] [Abstract][Full Text] [Related]
20. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]